Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Swedish Orphan Biovitrum AB (publ)
  6. News
  7. Summary
    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM AB (PUBL)

(SOBI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Swedish Orphan Biovitrum Gets Positive Opinion From European Medicines Agency For COVID-19 Pneumonia Treatment

12/16/2021 | 10:02am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
All news about SWEDISH ORPHAN BIOVITRUM AB (PUBL)
05/10Bulletin from Swedish Orphan Biovitrum (Sobi®)'s Annual General Meeting (AGM)
AQ
05/10Swedish Orphan Biovitrum AB Elects Bo Jesper Hansen as New Board Member
CI
04/28Swedish Orphan Biovitrum AB Reports Earnings Results for the First Quarter Ended March ..
CI
04/28TRANSCRIPT : Swedish Orphan Biovitrum AB, Q1 2022 Earnings Call, Apr 28, 2022
CI
04/28Swedish Drugmaker Sobi Confirms FY22 Revenue Outlook After Q1 Growth
MT
04/28Drugmaker Sobi books profit fall on restructuring, Russia
RE
04/28Sobi publishes Q1 2022 report
AQ
04/28Swedish Orphan Biovitrum AB Provides Earnings Guidance for the Year 2022
CI
04/20INVITATION : Sobi's Q1 2022 report
AQ
04/06Swedish Orphan Biovitrum AB - Annual and Sustainability Report 2021
AQ
More news
Analyst Recommendations on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
More recommendations
Financials
Sales 2022 17 553 M 1 784 M 1 784 M
Net income 2022 2 377 M 242 M 242 M
Net Debt 2022 6 950 M 706 M 706 M
P/E ratio 2022 26,7x
Yield 2022 -
Capitalization 62 101 M 6 312 M 6 312 M
EV / Sales 2022 3,93x
EV / Sales 2023 3,44x
Nbr of Employees 1 569
Free-Float 58,8%
Chart SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Duration : Period :
Swedish Orphan Biovitrum AB (publ) Technical Analysis Chart | SOBI | SE0000872095 | MarketScreener
Technical analysis trends SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 210,40 SEK
Average target price 245,88 SEK
Spread / Average Target 16,9%
EPS Revisions
Managers and Directors
Guido Oelkers President & Chief Executive Officer
Henrik Stenqvist Chief Financial Officer
Sven Håkan Björklund Chairman
Anne Marie de Jonge Schuermans Head-Technical Operations & Senior Vice President
Sven Anders Ullman Chief Medical Officer, Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
SWEDISH ORPHAN BIOVITRUM AB (PUBL)13.67%6 312
CSL LIMITED-7.46%92 708
SAMSUNG BIOLOGICS CO.,LTD.-7.64%47 463
BIOGEN INC.-14.05%30 198
WUXI BIOLOGICS (CAYMAN) INC.-41.33%29 183
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-32.02%20 229